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doi:10.1016/j.gmbhs.2012.04.004Abstract Alzheimer’s disease (AD) is the most common cause of dementia of late life. The
aim of this study was to utilize the proteomic approaches to establish serum protein patterns
of AD. By using nano-high-performance liquid chromatography/electrospray ionization tandem
mass spectrometry followed by peptide fragmentation pattern software to analyze proteome
in human serum, the activity-dependent neuroprotector homeobox protein was found to
exhibit significant differential expression compared with the control group and was confirmed
by Western blotting and enzyme-linked immunosorbent assay. It may play an important role in
slowing the progression of clinical symptoms of AD.
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Figure 1 ELISA analysis of ADNP expression in AD patients and
normal individuals. ADNP was down-regulated in the serum
samples of AD patients. For the AD group, ADNPwas not detected
in some serum samples, and some of the ELISA results were lower
than the detected limit value. Thus, the p value (*) of ADNP
concentration between AD patients and control individuals was
less than 0.05. AD Z Alzheimer’s disease; ADNP Z activity-
dependent neuroprotector homeobox protein; ELISAZ enzyme-
linked immunosorbent assay.
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Alzheimer’s disease (AD) is the most common cause of
dementia of late life, and is a devastating neurological
disorder accounting for about 50% of all dementias,
which involve multiple pathologies in the complex bio-
logical system of the brain.1 It is a progressive disease,
which means that gradually over time, more areas of the
brain will be damaged. As this happens, the symptoms
become more severe. Current clinical diagnosis of AD
requires a medical history, physical examinations, and
a series of neurological examinations including brain
imaging scans, neuropsychological assessments, and sup-
porting data with cerebrospinal fluid or blood test
findings.2e4 However, the definite diagnosis of AD can be
done only after death using the pathological diagnosis at
autopsy.
To enhance our understanding of the AD proteome, the
serum proteins were identified by nano-high-performance
liquid chromatography (nano-HPLC)/electrospray ioniza-
tion tandem mass spectrometry, followed by peptide frag-
mentation patterning. The database provides not only
information obtained from serum proteins of AD, but also
information on potential diagnostic protein biomarkers for
further investigation.
Materials and methods
Human serum specimens were collected from 45 early-
stage AD patients (ages: 63e84 years with a mean of 77.2)
and 20 normal individuals (ages: 55e84 years with a mean
of 72.3). The Human Experiment and Ethics Committee of
the Kaohsiung Medical University Hospital approved the
study protocol, and all participants enrolled in the study
signed informed consents. Serum samples were reduced,
alkylated, and then digested with trypsin using standard
protocols. The protein tryptic digests were fractionated
using a flow rate of 400 nL/min with a nano-HPLC system
(nanoACQUITY UPLC, Waters, Milford, MA, USA) coupled
with an ion trap mass spectrometer (LTQ Orbitrap
Discovery Hybrid FTMS, Thermo, San Jose, CA, USA)
equipped with an electrospray ionization source. A sample
(2 mL) of the desired peptide digest was loaded into
the reverse-phase column (Symmetry C18, 5 mm,
180 mm  20 mm) by an autosampler. The reverse-phase
separation was performed using a linear acetonitrile
gradient from 99% buffer A (100% deionized water/0.1%
formic acid) to 85% buffer B (100% acetonitrile/0.1% for-
mic acid) for 100 minutes using the micropump. The
separation is performed on a C18 microcapillary column
(BEH C18, 1.7 mm, 75 mm  100 mm) using the nano-
separation system. For protein identification, Mascot
software (Version 2.2.1, Matrix Science, London, UK) was
used to search the Swiss-Prot human protein sequence
database. Mowse scores of greater than 80 were consid-
ered significant (p < 0.05). The activity-dependent neu-
roprotector homeobox protein (ADNP) was confirmed by
Western blotting and enzyme-linked immunosorbent assay
(ELISA). The quantitative analysis of Western blotting was
carried out using the ImageQuant-TL-7.0 software, version
2010 (Amersham Biosciences, Uppsala, Sweden).Results
In this study, we performed proteomic approaches to
identify proteins differentiating AD from normal individ-
uals. When a protein was identified by three or more
unique peptides possessing Mascot scores that passed the
above criteria, no visual assessment of spectra was con-
ducted and the protein was considered to be present in
the sample. A total of approximately 154 unique proteins
were identified in serum samples with high levels of
confidence. When compared with the protein list from
normal serum samples in our study and others reported in
the literature, most of those proteins were present in
normal serum specimens and may not be associated with
AD. However, by using the quantitative analysissoftware
ImageQuant-TL-7.0, one protein, ADNP, remained down-
regulated or nondetectable in AD patients, who had five-
fold less than detected amounts in normal individuals. The
quantification of ADNP in serum samples was also
measured by the ELISA method (Fig. 1). The average
concentrations were 1.53  0.096 and 0.43  0.052 mg/mL
in the serum samples of normal individuals and AD
patients, respectively. Noticeably, ADNP was not detected
in some serum samples from AD. Thus the p value between
AD patients and control individuals was less than 0.05. The
area of receiver operating characteristics (ROC) curve in
95% confidence interval of ADNP was 0.972 (Fig. 2). The
ADNP concentration may serve as a new and direct indi-
cator of AD.
Figure 2 ROC curve analysis for ADNP in the serum of normal
individuals and AD patients. The estimated under the curves is
0.972. AD Z Alzheimer’s disease; ADNP Z activity-dependent
neuroprotector homeobox protein; ROC Z receiver operating
characteristics.
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ADNP (124 kDa) is a glial cell mediator of a vasoactive
intestinal peptide associated with neuroprotection and
essential for brain development. In the hippocampus,
cerebral cortex, and cerebellum, the highly conserved
ADNP gene is abundantly expressed.5 It is implicated in
maintenance of cell survival through modulation of p53
expression.6 ADNP also protects cerebral cortical neurons
against the major AD toxic peptide b-amyloid 1-42 andinhibits b-amyloid 1-40 aggregation in brain.7 Thus, the b-
amyloid aggregation and plaque formation in AD patients’
brain are probably caused by ADNP down-regulation, indi-
cating that ADNP may serve as an indicator for AD.
However, more clinical studies are required to verify these
results. In conclusion, ADNP may become a new screening
biomarker for AD.Acknowledgments
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